Mirati Therapeutics, Inc. (NASDAQ:MRTX) – Analysts at Oppenheimer Holdings lifted their FY2017 earnings per share (EPS) estimates for Mirati Therapeutics in a research note issued to investors on Thursday. Oppenheimer Holdings analyst L. Cann now expects that the biotechnology company will earn ($2.86) per share for the year, up from their prior forecast of ($3.02). Oppenheimer Holdings has a “Outperform” rating and a $18.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Mirati Therapeutics’ Q4 2017 earnings at ($0.74) EPS, Q1 2018 earnings at ($0.78) EPS, Q2 2018 earnings at ($0.82) EPS, Q3 2018 earnings at ($0.75) EPS and Q4 2018 earnings at ($0.86) EPS.

Several other research firms have also recently issued reports on MRTX. Zacks Investment Research cut Mirati Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Mirati Therapeutics in a research report on Thursday, October 12th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $13.00 target price on shares of Mirati Therapeutics in a research report on Thursday, October 12th. ValuEngine upgraded Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 15th. Finally, Cann assumed coverage on Mirati Therapeutics in a research report on Tuesday, September 19th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $14.14.

ILLEGAL ACTIVITY NOTICE: “Mirati Therapeutics, Inc. (MRTX) to Post FY2017 Earnings of ($2.86) Per Share, Oppenheimer Holdings Forecasts” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/07/mirati-therapeutics-inc-mrtx-to-post-fy2017-earnings-of-2-86-per-share-oppenheimer-holdings-forecasts.html.

Shares of Mirati Therapeutics (NASDAQ MRTX) opened at $13.65 on Monday.

Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.16.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Broadfin Capital LLC grew its holdings in Mirati Therapeutics by 19.1% during the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock valued at $9,091,000 after buying an additional 400,000 shares in the last quarter. Sabby Management LLC grew its holdings in Mirati Therapeutics by 2.1% during the 2nd quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock valued at $921,000 after buying an additional 5,365 shares in the last quarter. Royce & Associates LP grew its holdings in Mirati Therapeutics by 88.7% during the 2nd quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock valued at $917,000 after buying an additional 118,063 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Mirati Therapeutics by 53.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock valued at $728,000 after buying an additional 69,377 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Mirati Therapeutics during the 1st quarter valued at approximately $854,000. Institutional investors and hedge funds own 60.26% of the company’s stock.

In other Mirati Therapeutics news, SVP Jamie Christensen sold 7,499 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total transaction of $104,986.00. Following the completion of the transaction, the senior vice president now owns 10,169 shares in the company, valued at approximately $142,366. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 12,269 shares of company stock valued at $170,226 in the last 90 days. 5.10% of the stock is currently owned by company insiders.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Earnings History and Estimates for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.